Company profile for C4 Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

C4 Therapeutics® is committed to transforming the treatment of cancer, neurological, and other important diseases with novel therapies that eliminate disease-causing proteins. Our approach to medicine harnesses the innate machinery of the cell to attack disease and potentially bring deep and durable responses to patients. C4 Therapeutics is pioneering a new class of drugs. C4’s technology platform produces small molecule dr...
C4 Therapeutics® is committed to transforming the treatment of cancer, neurological, and other important diseases with novel therapies that eliminate disease-causing proteins. Our approach to medicine harnesses the innate machinery of the cell to attack disease and potentially bring deep and durable responses to patients. C4 Therapeutics is pioneering a new class of drugs. C4’s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
490 Arsenal Way, Suite 200 Watertown, MA 02472
Telephone
Telephone
(617) 231-0700
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/25/3194174/0/en/C4-Therapeutics-to-Participate-in-the-8th-Annual-Evercore-Healthcare-Conference.html

GLOBENEWSWIRE
25 Nov 2025

https://www.globenewswire.com/news-release/2025/10/16/3167794/0/en/C4-Therapeutics-Announces-Pricing-of-125-Million-Underwritten-Offering.html

GLOBENEWSWIRE
16 Oct 2025

https://www.globenewswire.com/news-release/2025/10/01/3159347/0/en/C4-Therapeutics-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Pfizer-for-the-Combination-of-Cemsidomide-and-Elranatamab-for-the-Treatment-of-Relapsed-Refractory-.html

GLOBENEWSWIRE
01 Oct 2025

https://www.globenewswire.com/news-release/2025/09/20/3153507/0/en/C4-Therapeutics-Presents-Cemsidomide-Phase-1-Multiple-Myeloma-Data-Supporting-Potential-Best-in-Class-Profile-at-the-International-Myeloma-Society-Annual-Meeting.html

GLOBENEWSWIRE
20 Sep 2025

https://www.globenewswire.com/news-release/2025/09/04/3144324/0/en/C4-Therapeutics-Highlights-Recent-Achievement-in-Biogen-Collaboration.html

GLOBENEWSWIRE
04 Sep 2025

https://www.globenewswire.com/news-release/2025/09/03/3143439/0/en/C4-Therapeutics-to-Present-Data-from-the-Phase-1-Trial-of-Cemsidomide-in-Multiple-Myeloma-at-the-International-Myeloma-Society-IMS-Annual-Meeting.html

GLOBENEWSWIRE
03 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty